Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) and keeping the ...
Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, ...
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its lead clinical programs, ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Rarely, the skin may be affected as well. When this condition affects the lungs, it causes emphysema, a form of chronic obstructive pulmonary disease. Alpha-1-antitrypsin (AAT) is a protein produced ...
Alpha-1 antitrypsin (AAT) deficiency is a rare genetic disorder that is passed on in families and can affect the lungs, liver and/or skin. When this condition affects the lungs, it causes COPD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback